Levofloxacin to prevent bloodstream infections after stem cell transplantation
Tests levofloxacin against placebo to prevent infections after donor stem cell transplantation.
Key facts
- Who runs it
- HUS-yhtymae
- Where
- Helsinki, FinlandSee the site
- Trial code
- Registry title
- Antibiotic Prophylaxis in Hematopoietic Stem Cell Transplantation: a Randomised Controlled Trial - The ANTURA trial
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 150 people, planned
- Started
- 5 Oct 2026
- Expected to end
- 15 Apr 2030
- Type of study
- Interventional
- Record updated
- 23 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are about to have a stem cell transplant from a donor at Helsinki University Hospital. It tests whether the antibiotic levofloxacin lowers blood infections after the transplant, compared with placebo.
- Age
- 18 to 64 years
- Sex
- Women and men can join.
- Disease stage
- Adults planned for a donor (allogeneic) stem cell transplant for any accepted reason.
Main reasons for not taking part
- Known allergy to fluoroquinolone antibiotics
- Epilepsy or another known seizure disorder
- Long-QT syndrome, or a QT time (cQT) above 500ms
- Past tendon problems during fluoroquinolone treatment
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adults (≥18 years) scheduled to undergo allogeneic hematopoietic stem cell transplantation at Helsinki University Hospital for any accepted indication
Who cannot take part
- Known hypersensitivity to fluoroquinolone antibiotics
- Epilepsy or other known seizure disorder
- History of tendinopathy during fluoroquinolone therapy
- Long-QT syndrome
- Acquired prolonged QT-time, cQT>500ms
- Pregnancy of breastfeeding
- Other known contraindication to levofloxacin or other fluoroquinolone antibiotics
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Finland
- HUS-YhtymaeHelsinki, FinlandNot yet recruiting
About the trial
What the trial wants to find out
The primary objective of this study is to evaluate whether antibacterial prophylaxis with levofloxacin reduces the incidence of bloodstream infections during the neutropenic phase (up to 30 days) following allogeneic hematopoietic stem cell transplantation compared with placebo.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Antibiotic Prophylaxis in Hematopoietic Stem Cell Transplantation: a Randomised Controlled Trial - The ANTURA trial
- Plain-language title
- Levofloxacin to prevent bloodstream infections after stem cell transplantationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-524982-25-00, who can take part
- Record updated
- 23 September 2026